Immune checkpoint inhibitors and their impact on liver enzymes and attenuation.
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation.
复制标题
DOI：
10.1186/s12885-022-10090-9
复制
发表时间：
2022-09-20
期刊：
影响因子：
3.8
通讯作者：
Johnson, Douglas B.
中科院分区：
文献类型：
--
作者：
Park, Benjamin C.;Lee, Aaron X. T.;Ye, Fei;Turker, Isik;Johnson, Douglas B.
关键词：
影响肝脏的免疫相关不良事件在免疫检查点抑制剂（ICI）治疗中很常见;然而，关于ICI对肝脏炎症的亚临床影响的数据很少。该研究旨在确定ICI治疗是否影响伴有和不伴有肝脂肪变性的黑色素瘤患者的肝衰减和肝酶。对在范德比尔特大学医学中心（VUMC）接受ICI治疗并接受系列PET-CT扫描的晚期黑色素瘤患者进行了一项回顾性队列研究。主要结局包括：通过PET-CT/非造影CT和肝酶测量的肝脏衰减。肝脏脂肪变性由放射科医师根据临床影像学诊断。在839例接受ICI治疗的晚期黑色素瘤患者中，81例患者接受了间隔约12个月的连续PET-CT扫描，并长期存活;其中11例患者既存脂肪变性/脂肪性肝炎。总体而言，ICI与所有患者的肝酶显著升高无关;在既存脂肪变性/脂肪性肝炎患者中观察到肝酶适度降低。同样，肝脏衰减从基线到治疗后也没有变化（58.44 vs 60.60 HU，+ 2.17，p = 0.055）。ICI可能不会长期影响一般人群或既存脂肪变性/脂肪性肝炎患者的肝酶或肝衰减，这是肝脏脂肪含量和炎症的非侵入性测量。在线版本包含补充材料，可通过10.1186/s12885-022-10090-9获得。
Immune related adverse events impacting the liver are common from immune checkpoint inhibitor (ICI) therapy; however, there is little data regarding the subclinical impact of ICIs on liver inflammation. The study aims to determine whether ICI therapy affects liver attenuation and liver enzymes in melanoma patients with and without hepatic steatosis. A retrospective, cohort study was conducted of patients with advanced melanoma treated with ICI therapy who received serial PET-CT scans at the Vanderbilt University Medical Center (VUMC). Primary outcomes included: liver attenuation measured by PET-CT/non-contrast CT and liver enzymes. Hepatic steatosis was diagnosed by radiologists on clinical imaging. Among 839 patients with advanced melanoma treated with ICIs, 81 had serial PET-CT scans approximately 12 months apart and long-term survival; of these 11 patients had pre-existing steatosis/steatohepatitis. Overall, ICI was not associated with significant increases in liver enzymes in all patients; modest decreases in liver enzymes were observed in patients with pre-existing steatosis/steatohepatitis. Similarly, liver attenuation did not change from baseline to post-treatment (58.44 vs 60.60 HU, + 2.17, p = 0.055). ICIs may not chronically affect liver enzymes or liver attenuation, a non-invasive measure of liver fat content and inflammation, in the general population or in those with pre-existing steatosis/steatohepatitis. The online version contains supplementary material available at 10.1186/s12885-022-10090-9.
登录
查看更多内容
影响因子：
15.9
作者：
Gotsman, Israel;Grabie, Nir;Lichtman, Andrew H.
通讯作者：
Lichtman, Andrew H.
DOI：
10.1056/nejmoa2029349
发表时间：
2021-10-21
期刊：
The New England journal of medicine
影响因子：
--
作者：
Sanyal AJ;Van Natta ML;Clark J;Neuschwander-Tetri BA;Diehl A;Dasarathy S;Loomba R;Chalasani N;Kowdley K;Hameed B;Wilson LA;Yates KP;Belt P;Lazo M;Kleiner DE;Behling C;Tonascia J;NASH Clinical Research Network (CRN)
通讯作者：
NASH Clinical Research Network (CRN)
影响因子：
5.5
作者：
Barrett, JF;Keat, N
通讯作者：
Keat, N
影响因子：
50.5
作者：
Menzies, A. M.;Johnson, D. B.;Long, G. V.
通讯作者：
Long, G. V.
影响因子：
10.9
作者：
Halle BR;Betof Warner A;Zaman FY;Haydon A;Bhave P;Dewan AK;Ye F;Irlmeier R;Mehta P;Kurtansky NR;Lacouture ME;Hassel JC;Choi JS;Sosman JA;Chandra S;Otto TS;Sullivan R;Mooradian MJ;Chen ST;Dimitriou F;Long G;Carlino M;Menzies A;Johnson DB;Rotemberg VM
通讯作者：
Rotemberg VM